Professor Yehui Shi: The Epigenetic Regulation of HR+ Metastatic Breast Cancer—A Review of the Development Path of HDACi Entinostat

Professor Yehui Shi: The Epigenetic Regulation of HR+ Metastatic Breast Cancer—A Review of the Development Path of HDACi Entinostat

Histone deacetylases (HDACs) are overexpressed in various tumors and are closely related to tumor progression and drug resistance. In hormone receptor-positive (HR+) breast cancer, HDAC overexpression leads to resistance to endocrine therapy and CDK4/6 inhibitors. The targeted application of HDAC inhibitors (HDACi) can effectively block this process, bringing better prognosis to patients. Entinostat, introduced in 1997, has undergone over two decades of meticulous research and development, and has become the first HDACi to achieve overall survival (OS) benefits in patients with HR+ metastatic breast cancer in China, offering new treatment options for Chinese patients. Professor Yehui Shi from the Tianjin Medical University Cancer Hospital will review the milestone events in the clinical exploration and application of HDACi entinostat in breast cancer, allowing the light of epigenetic regulation to shine on patients with HR+ metastatic breast cancer.
World Breast Cancer Awareness Month | Renowned Physicians’ Protection, Building a Healthy Future Together —— Focusing on Breast Cancer Prevention and Treatment (2)

World Breast Cancer Awareness Month | Renowned Physicians’ Protection, Building a Healthy Future Together —— Focusing on Breast Cancer Prevention and Treatment (2)

Breast cancer is one of the most common malignant tumors in women and is often referred to as the "pink killer," posing a serious threat to women's health. The World Health Organization has designated October as "World Breast Cancer Awareness Month" (also known as Pink Ribbon Month) to raise women's awareness of breast cancer prevention. The motto of the Pink Ribbon Breast Cancer Prevention Campaign is "early prevention, early detection, and early treatment." To enhance women's awareness of breast cancer prevention and treatment, Edding Group Company Limited, in collaboration with "Oncology Frontier," has specially invited leading domestic experts in the field of breast cancer. Combining clinical practice and research results, they have in-depth discussions on the importance of early screening, precise treatment, and healthy lifestyles for breast cancer.
World Breast Cancer Awareness Month | Renowned Physicians’ Protection, Building a Healthy Future Together —— Focusing on Breast Cancer Prevention and Treatment (1)

World Breast Cancer Awareness Month | Renowned Physicians’ Protection, Building a Healthy Future Together —— Focusing on Breast Cancer Prevention and Treatment (1)

Breast cancer is one of the most common malignant tumors in women and is often referred to as the "pink killer," posing a serious threat to women's health. The World Health Organization has designated October as "World Breast Cancer Awareness Month" (also known as Pink Ribbon Month) to raise women's awareness of breast cancer prevention. The motto of the Pink Ribbon Breast Cancer Prevention Campaign is "early prevention, early detection, and early treatment." To enhance women's awareness of breast cancer prevention and treatment, Edding Group Company Limited, in collaboration with "Oncology Frontier," has specially invited leading domestic experts in the field of breast cancer. Combining clinical practice and research results, they have in-depth discussions on the importance of early screening, precise treatment, and healthy lifestyles for breast cancer.